Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies-Reference-Cited by-同舟云学术

Three‐year follow‐up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non‐small cell lung cancer: Pooled analysis of ONO‐4538‐05 and ONO‐4538‐06 studies

Published:2019-07-29 Issue:11 Volume:8 Page:5183-5193
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Horinouchi Hidehito¹^ORCID,Nishio Makoto²^ORCID,Hida Toyoaki³,Nakagawa Kazuhiko⁴,Sakai Hiroshi⁵,Nogami Naoyuki⁶,Atagi Shinji⁷,Takahashi Toshiaki⁸,Saka Hideo⁹,Takenoyama Mitsuhiro¹⁰,Katakami Nobuyuki¹¹,Tanaka Hiroshi¹²,Takeda Koji¹³,Satouchi Miyako¹⁴,Isobe Hiroshi¹⁵,Maemondo Makoto¹⁶¹⁷,Goto Koichi¹⁸,Hirashima Tomonori¹⁹,Minato Koichi²⁰,Sumiyoshi Naoki²¹,Tamura Tomohide²²

Affiliation:

1. Department of Thoracic Oncology National Cancer Center Hospital Tokyo Japan

2. Department of Thoracic Medical Oncology Cancer Institute Hospital Tokyo Japan

3. Department of Thoracic Oncology Aichi Cancer Center Hospital Nagoya Japan

4. Department of Medical Oncology, Faculty of Medicine Kindai University Osaka Japan

5. Department of Thoracic Oncology Saitama Cancer Center Saitama Japan

6. Division of Thoracic Oncology and Medicine National Hospital Organization Shikoku Cancer Center Ehime Japan

7. Department of Internal Medicine Kinki‐Chuo Chest Medical Center Sakai Japan

8. Division of Thoracic Oncology Shizuoka Cancer Center Shizuoka Japan

9. Department of Medical Oncology Nagoya Medical Center Nagoya Japan

10. Department of Thoracic Oncology National Hospital Organization Kyushu Cancer Center Fukuoka Japan

11. Department of Medical Oncology Kobe City Medical Center Kobe Japan

12. Department of Internal Medicine Niigata Cancer Center Hospital Niigata Japan

13. Department of Medical Oncology Osaka City General Hospital Osaka Japan

14. Department of Thoracic Oncology Hyogo Cancer Center Hyogo Japan

15. Department of Medical Oncology KKR Sapporo Medical Center Sapporo Japan

16. Division of Pulmonary Medicine, Allergy and Rheumatology, Department of Internal Medicine Iwate Medical University School of Medicine Iwate Japan

17. Department of Respiratory Medicine Miyagi Cancer Center Miyagi Japan

18. Division of Thoracic Oncology National Cancer Center Hospital East Chiba Japan

19. Department of Thoracic Oncology Osaka Habikino Medical Center Osaka Japan

20. Division of Respiratory Medicine Gunma Prefectural Cancer Center Gunma Japan

21. Oncology Clinical Development Planning Ono Pharmaceutical Co., Ltd Osaka Japan

22. Thoracic Center St. Luke's International Hospital Tokyo Japan

Funder

Bristol-Myers Squibb

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.2411

Reference21 articles.

1. Long-term Realism and Cost-effectiveness: Primary Prevention in Combatting Cancer and Associated Inequalities Worldwide

2. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

3. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

4. Second-line treatment for advanced NSCLC without actionable mutations: is immunotherapy the ‘panacea’ for all patients?

5. The blockade of immune checkpoints in cancer immunotherapy

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Delayed-Onset Immune-Related Colitis Following Pancreaticoduodenectomy in Patients With Gastric Cancer and Pancreatic Invasion Treated With Immune Checkpoint Inhibitors;Cureus;2024-09-02

2. Evaluation of the efficacy and safety of nivolumab in the second- or later-line treatment of patients with locally advanced/metastatic non-small cell lung cancer in Türkiye: a retrospective multicenter non-interventional registry study;Current Medical Research and Opinion;2024-06-22

3. First‐line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non‐squamous non‐small cell lung cancer: Updated survival analysis of the ONO‐4538‐52/TASUKI‐52 randomized controlled trial;Cancer Medicine;2023-08

4. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis;Frontiers in Immunology;2023-07-13

5. Anticuerpos inmunomoduladores en el tratamiento del cáncer;Revista Repertorio de Medicina y Cirugía;2023-03-01